Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.36USD
19 Oct 2017
Change (% chg)

$-0.02 (-5.18%)
Prev Close
$0.38
Open
$0.38
Day's High
$0.38
Day's Low
$0.34
Volume
456,165
Avg. Vol
746,680
52-wk High
$1.00
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Cytrx corp says ‍Nasdaq has granted co's request for a continued listing
Monday, 16 Oct 2017 08:20pm EDT 

Oct 16 (Reuters) - Cytrx Corp ::Cytrx corp - ‍Nasdaq has granted co's request for a continued listing pending results of a stockholder vote on or before October 30, 2017​.  Full Article

Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
Thursday, 12 Oct 2017 09:00am EDT 

Oct 12 (Reuters) - Cytrx Corp ::Cytrx Corporation highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions planned by Licensee Nantcell, Inc..  Full Article

Cytrx Corporation announces $8.1 mln registered direct offering of common stock
Tuesday, 13 Dec 2016 09:00am EST 

Cytrx Corp : Cytrx Corporation announces $8.1 million registered direct offering of common stock .Cytrx corp - entered into securities purchase agreements to purchase shares of stock at purchase price of $0.42 per share.  Full Article

Cytrx reports loss per share of $0.27 for Q2 2016
Friday, 29 Jul 2016 09:00am EDT 

Cytrx Corp :Q2 loss per share $0.27.  Full Article

Cytrx Corp announces pricing of $20 mln public offering
Friday, 15 Jul 2016 07:30am EDT 

Cytrx Corp : Cytrx Corp announces pricing of $20 million public offering of common stock and warrants . Priced offering of an aggregate of approximately 28.6 million shares of common stock at a price to public of $0.70 per share .Investors will also receive warrants to purchase up to approximately 28.6 million shares with an exercise price of $0.70 per share.  Full Article

CytRx presents updated Aldoxorubicin trial results
Monday, 6 Jun 2016 09:00am EDT 

CytRx Corp : Cytrx Corp says clinical data presented at asco continues to support safety and activity of aldoxorubicin in multiple high unmet need tumor types .Cytrx presents updated aldoxorubicin clinical trial results at the 2016 american society of clinical oncology annual meeting.  Full Article

Cytrx Corp issued 1.6 mln shares for benefit of claimants of IN RE Cytrx securities litigation
Friday, 27 May 2016 12:35pm EDT 

: Cytrx Corp says on May 25, 2016, issued for benefit of claimants in matter of IN RE Cytrx Securities litigation total of 1.6 million shares of stock . Cytrx Corp says shares were issued pursuant to court's judgment and order granting final approval of previously announced settlement of matter . Cytrx Corp says for purposes of this settlement, the shares were valued at an aggregate of $4.5 million - SEC Filing Source - http://1.usa.gov/1U0Sgqg (Bengaluru Newsroom; +1 646 223 8780).  Full Article

CytRx reports Q1 loss per share $0.19
Wednesday, 11 May 2016 09:11am EDT 

CytRx Corp : CytRx reports first quarter 2016 financial results . Q1 loss per share $0.19 .Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article